|
|
||||||||
Viewpoint |
Department of Integrative Medical Sciences, NEOUCOM, Rootstown, OH 44272-0095
SUMMARY
Ligand functional selectivity occurs when full agonists at a single type of G protein–coupled receptor differ in their abilities to activate intracellular signaling pathways. Membrane rafts are cholesterol and sphingolipid-enriched areas of the cell membrane that tether signal protein complexes. Recent data suggests that functional selectivity of signaling through the µ opiate receptor depends on location of receptor and G proteins in raft or nonraft membrane domains. Changes in the distribution of signaling molecules in different membrane domains with age, disease, or drug history may contribute to variations in signaling and drug effects. Other results suggest that functional selectivity may account for therapeutic advantages of certain beta blockers used to treat heart failure. Functional selectivity could be exploited to develop drugs with more therapeutic value and fewer side effects.
This article has been cited by other articles:
![]() |
A. Russo, U. J. K. Soh, and J. Trejo Proteases Display Biased Agonism at Protease-Activated Receptors: Location matters! Mol. Interv., April 1, 2009; 9(2): 87 - 96. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. van Rijn and J. L. Whistler The Only Way Is Up: Preventing Opioid Tolerance by Promoting Cell Surface Expression of MOR-DOR Heterodimers? Mol. Interv., December 1, 2008; 8(6): 277 - 280. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ASPET Journals | Pharmacological Reviews | Drug Metabolism and Disposition |
| Molecular Interventions | Molecular Pharmacology | J Pharmacology and Exp Therapeutics |